These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2110274)

  • 1. [Incidence of pathologic ammonia concentrations in the plasma in children with seizure disorders treated with Convulsofin/Convulex and other anticonvulsants in comparison with children with brain damage and healthy children].
    Wiedemann G; Haupt M; Rommel A; Rommel KF; Biesenbach R; Schmidt W
    Kinderarztl Prax; 1990 Jan; 58(1):21-7. PubMed ID: 2110274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs.
    Thom H; Carter PE; Cole GF; Stevenson KL
    Dev Med Child Neurol; 1991 Sep; 33(9):795-802. PubMed ID: 1936631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.
    Verrotti A; Greco R; Morgese G; Chiarelli F
    Int J Clin Lab Res; 1999; 29(1):36-40. PubMed ID: 10356662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of carnitine supplementation in valproate-induced hyperammonaemia.
    Böhles H; Sewell AC; Wenzel D
    Acta Paediatr; 1996 Apr; 85(4):446-9. PubMed ID: 8740302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymptomatic hyperammonemia in children treated with valproic acid.
    Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
    J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
    [No Abstract]   [Full Text] [Related]  

  • 6. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of valproate therapy on thrombin generation determined by calibrated automated thrombography.
    Topf HG; Lischetzki G; Trollmann R; Rascher W; Rauh M
    Klin Padiatr; 2011 May; 223(3):165-8. PubMed ID: 21472635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproate therapy does not deplete carnitine levels in otherwise healthy children.
    Hirose S; Mitsudome A; Yasumoto S; Ogawa A; Muta Y; Tomoda Y
    Pediatrics; 1998 May; 101(5):E9. PubMed ID: 9565442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood ammonia levels in epileptic children on 2 dose ranges of valproic acid monotherapy: a cross-sectional study.
    Sharma S; Gulati S; Kabra M; Kalra V; Vasisht S; Gupta YK
    J Child Neurol; 2011 Jan; 26(1):109-12. PubMed ID: 20921570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet.
    Coppola G; Epifanio G; Auricchio G; Federico RR; Resicato G; Pascotto A
    Brain Dev; 2006 Jul; 28(6):358-65. PubMed ID: 16376041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for hyperammonemia in pediatric patients with epilepsy.
    Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproate-induced eosinophilia in children with epilepsy: role of interleukin-5.
    Makis AC; Tzoufi M; Kateri MD; Bourantas KL; Papadopoulou ZL
    J Child Neurol; 2005 Feb; 20(2):150-2. PubMed ID: 15794184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum carnitine, beta-hydroxybutyrate and ammonia levels during valproic acid therapy.
    Toksoy HB; Tanzer FN; Atalay A
    Turk J Pediatr; 1995; 37(1):25-9. PubMed ID: 7732605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rapid change to monotherapy with valproic acid in children.
    Hurst DL
    J Child Neurol; 1993 Oct; 8(4):357-9. PubMed ID: 8228032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.
    Ratnaike RN; Schapel GJ; Purdie G; Rischbieth RH; Hoffmann S
    Br J Clin Pharmacol; 1986 Jul; 22(1):100-3. PubMed ID: 3091053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperaminoacidemia in epileptic children treated with valproic acid.
    Castro-Gago M; Rodrigo-Saez E; Novo-Rodriguez I; Camiña MF; Rodriguez-Segade S
    Childs Nerv Syst; 1990 Dec; 6(8):434-6. PubMed ID: 2095300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.